XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.4
Summary of Significant Accounting Policies Summary of Significant Accounting Principles (Tables)
 6 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Schedule of Other Nonoperating Income (Expense)
The following table summarizes the components of other income (expense), net.
 Three Months Ended December 31, Six Months Ended December 31,
2024202320242023
Gains (losses) on derivatives not designated as hedging instruments (1)$33,632 $(13,668)$13,063 $(5,356)
Currency-related (losses) gains, net (2)(2,107)13,062 6,560 10,363 
Other gains
153 215 563 1,021 
Total other income (expense), net$31,678 $(391)$20,186 $6,028 
_____________________
(1) Includes realized and unrealized gains and losses on derivative currency forward and option contracts not designated as hedging instruments. For contracts not designated as hedging instruments, we realized gains of $2,981 and $749 for the three and six months ended December 31, 2024, respectively, and losses of $2,539 and $488 for the three and six months ended December 31, 2023, respectively. Refer to Note 4 for additional details relating to our derivative contracts.
(2) Currency-related (losses) gains, net primarily relates to significant non-functional currency intercompany financing relationships that we may change at times and are subject to currency exchange rate volatility. In addition, during the three and six months ended December 31, 2023, we recognized gains of $2,230 and $294, respectively, on a cross-currency swap designated as a cash flow hedge which hedges the remeasurement of an intercompany loan. We did not hold any cross-currency swap contracts that were designated as cash flow hedges during the three and six months ended December 31, 2024. Refer to Note 4 for additional details regarding our cash flow hedges.
Schedule of Weighted Average Number of Shares
The following table sets forth the reconciliation of the weighted-average number of ordinary shares.
 Three Months Ended December 31, Six Months Ended December 31,
 2024202320242023
Weighted average shares outstanding, basic
24,965,612 26,609,929 25,066,729 26,539,349 
Weighted average shares issuable upon exercise/vesting of outstanding share options/PSUs/RSUs/warrants (1)940,539 569,144 1,078,723 589,915 
Shares used in computing diluted net income per share attributable to Cimpress plc25,906,151 27,179,073 26,145,452 27,129,264 
Weighted average anti-dilutive shares excluded from diluted net income per share attributable to Cimpress plc299,877 192,204 153,799 189,927 
__________________
(1) On May 1, 2020, we entered into a financing arrangement which included 7-year warrants to purchase 1,055,377 of our ordinary shares with a strike price of $60 that have a potentially dilutive impact on our weighted average shares outstanding. The weighted average dilutive effect of the warrants for the three and six months ended December 31, 2024 were 248,156 and 294,657, respectively, and for the three and six months ended December 31, 2023 were 146,506 and 122,412, respectively.